57 participants
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-11
- Start Date:
- 2026-08-16
- Completion:
- 2030-06-30
Conditions
- B-All
- Acute Lymphoblastic Leukemia
Interventions
- BIOLOGICAL
- DRUG
No Results Yet